Skip to main content
. 2021 Sep 16;12:744826. doi: 10.3389/fphar.2021.744826

FIGURE 4.

FIGURE 4

Anlotinib represses PCBP3 expression levels during myofibroblast activation. (A) Immunofluorescence for PCBP3 (green) in mouse lung fibroblasts treated with anlotinib for 3  h, followed by TGF-β1 for an additional 24 h. DAPI-stained nuclei (blue). Scale bar, 25 µm. (B) Western blots analysis of PCBP3 and β-actin in primary mouse lung fibroblasts. (C) Quantification for the indicated proteins (mean ± SD, n = 3). (D) The Western blots analysis of PCBP3 and β-actin in IMR90 cells treated with anlotinib for 3  h, followed by TGF-β1 for an additional 24 h. (E) Quantification for the indicated proteins (mean ± SD, n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 VS TGF-β1-treated group by ANOVA.